Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05506943 · ClinicalTrials.gov registry record · Phase 2

A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)

A Phase 2 study of Cholangiocarcinoma and Biliary Tract Cancer, sponsored by Compass Therapeutics.

Active
Registry status
Phase 2
Development phase
150
Enrollment target
20
Study locations

NCT05506943 is a Phase 2 study of Cholangiocarcinoma and Biliary Tract Cancer that is active but no longer recruiting, run by Compass Therapeutics. The registered enrollment target is 150 participants, below the 383-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (61% lower). The trial reports 20 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05506943, a Phase 2 study of Cholangiocarcinoma and Biliary Tract Cancer, is active but no longer recruiting, sponsored by Compass Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
150 participants
Enrollment target
20
Study locations

Study Summary

This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.

Conditions Studied

Cholangiocarcinoma Biliary Tract Cancer Gall Bladder Cancer Ampullary Cancer

Interventions

  • DRUG Paclitaxel
  • DRUG CTX-009

Study Locations (20)

California

  • University of Southern California Norris Comprehensive Cancer Center - Los Angeles
  • Stanford Medicine Cancer Center - Palo Alto
  • University of California San Francisco - San Francisco

Florida

  • University of Florida - Gainesville
  • Mayo Clinic Jacksonville - Jacksonville
  • AdventHealth Orlando - Orlando

Arizona

  • Mayo Clinic Arizona - Phoenix
  • University of Arizona - Tucson

Illinois

  • Northwestern University - Chicago
  • University of Chicago - Chicago

New Mexico

  • The University of New Mexico - Albuquerque
  • Memorial Medical Center - Las Cruces

Colorado

  • Rocky Mountain Cancer Centers, LLP - Aurora

Louisiana

  • Ochsner Clinic Foundation - New Orleans

Maryland

  • Johns Hopkins University - Baltimore

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2023-01-09
Est. Completion 2025-12
Phase Phase 2

Sponsor

Compass Therapeutics

5 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05506943

The ClinicalTrials.gov registry entry for NCT05506943 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 383-participant average among 60 other Cholangiocarcinoma trials with a reported enrollment target (61% lower). The listed sponsor is Compass Therapeutics, which has 5 total studies on file at ClinicalTrials.gov.

The record links to 4 conditions, with Cholangiocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which Paclitaxel is the first listed.

NCT05506943 reports 20 study locations spanning 13 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT05506943 about?

NCT05506943 is a clinical study titled "A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)". This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.

What is the current status of trial NCT05506943?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 150 participants. The study started on 2023-01-09. Estimated completion is 2025-12.

What conditions does trial NCT05506943 study?

This clinical trial studies the following conditions: Cholangiocarcinoma, Biliary Tract Cancer, Gall Bladder Cancer, Ampullary Cancer.

What interventions are being tested in trial NCT05506943?

The interventions under investigation include: Paclitaxel (DRUG), CTX-009 (DRUG).

Who is sponsoring clinical trial NCT05506943?

This trial is sponsored by Compass Therapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05506943 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cholangiocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cholangiocarcinoma

All registered trials for this condition

Biliary Tract Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.